Short answer
Aclaris Therapeutics, Inc. (ACRS) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $2M (down 8.3% year over year) with net income of −$22M.
Q2 2026 key financials · XBRL
- Revenue
- $2M
- −8.3% YoY · −18.4% QoQ
- Net income
- −$22M
- −39.4% YoY · −8.5% QoQ
- Operating margin
- -1487.9%
- EPS (diluted)
- −$0.15
- −15.4% YoY · +0.0% QoQ
Source: XBRL data from the Aclaris Therapeutics, Inc. (ACRS) Q2 2026 10-Q on SEC EDGAR. USD.
Aclaris Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability, margin, or net-income percentages provided in the excerpt
- Forward-looking statements subject to risks and uncertainties; no specific outlook or updated guidance disclosed in the excerpt
Risk Factors
- No risk-factors section provided; submitted text contains only trading-arrangement disclosures, exhibits, and signatures
- No newly added or materially updated risk identified in the provided excerpt
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aclaris Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.